Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Millennium Pharmacon International Tbk (SDPC.JK)
Jakarta Selatan, ID
PT Millennium Pharmacon International Tbk is an Indonesian enterprise specializing in the wholesale and provision of a diverse range of healthcare products. This includes both prescription and over-the-counter medicines, nutritional supplements, and medical equipment. The company's comprehensive distribution channels extend to various points of sale, such as retail pharmacies, hospitals, supermarkets, and other retail establishments. As of December 31, 2021, it managed 33 regional offices strategically located across Indonesia's major islands, including Java, Bali, Sumatera, Kalimantan, and Sulawesi. Founded in 1952, the organization was originally known as PT NVPD Soedarpo Corporation Tbk before adopting its current designation, PT Millennium Pharmacon International Tbk, in February 1990. Its corporate headquarters are situated in Jakarta Selatan, Indonesia, and it operates as a subsidiary of Pharmaniaga International Corporation Sdn. Bhd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.05% | +2.17% | -0.53% | -5.05% | +36.23% | +18.24% | +41.35% | +38.24% | +41.35% | +133.63% | +50.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+4.9% Q1'26: +3.9% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+127.4% ★ Q1'26: -2.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.3% ★ Q1'26: -6.2% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+3.2% ★ Q1'26: +2.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+9.6% ★ Q1'26: +7.7% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×5.29× Q1'26: 6.38× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-15 | A- | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aris Sulistyanto | Head of the Internal Audit | — | — |
| Dedi K. Martadiredja | Senior Manager of Sales | — | — |
| Imam Fathorrahman | President Director | — | — |
| Mohamad Fazly Bin Hassan | Finance Director & Director | — | male |
| Morsela | Manager of Marketing | — | — |
| Olga Indria Bolang | Corporate Secretary | — | female |
| Puji Hartono | Head of Business & Operation Unit | — | — |
| Yungkis Sucandra | Head of Finance & Accounting Unit | — | — |
| Yuni Arrivani | Deputy Senior Manager of HRGA & Legal | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SDPC.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
